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Abstract
Astrogliosis, a cellular response characterized by astrocytic hypertrophy and accumulation of GFAP, is a hallmark of all types
of central nervous system (CNS) injuries. Potential signaling mechanisms driving the conversion of astrocytes into ‘‘reactive’’
phenotypes differ with respect to the injury models employed and can be complicated by factors such as disruption of the
blood-brain barrier (BBB). As denervation tools, neurotoxicants have the advantage of selective targeting of brain regions
and cell types, often with sparing of the BBB. Previously, we found that neuroinflammation and activation of the JAK2-STAT3
pathway in astrocytes precedes up regulation of GFAP in the MPTP mouse model of dopaminergic neurotoxicity. Here we
show that multiple mechanistically distinct mouse models of neurotoxicity (MPTP, AMP, METH, MDA, MDMA, KA, TMT)
engender the same neuroinflammatory and STAT3 activation responses in specific regions of the brain targeted by each
neurotoxicant. The STAT3 effects seen for TMT in the mouse could be generalized to the rat, demonstrating cross-species
validity for STAT3 activation. Pharmacological antagonists of the neurotoxic effects blocked neuroinflammatory responses,
pSTAT3tyr705 and GFAP induction, indicating that damage to neuronal targets instigated astrogliosis. Selective deletion of
STAT3 from astrocytes in STAT3 conditional knockout mice markedly attenuated MPTP-induced astrogliosis. Monitoring
STAT3 translocation in GFAP-positive cells indicated that effects of MPTP, METH and KA on pSTAT3tyr705 were localized to
astrocytes. These findings strongly implicate the STAT3 pathway in astrocytes as a broadly triggered signaling pathway for
astrogliosis. We also observed, however, that the acute neuroinflammatory response to the known inflammogen, LPS, can
activate STAT3 in CNS tissue without inducing classical signs of astrogliosis. Thus, acute phase neuroinflammatory responses
and neurotoxicity-induced astrogliosis both signal through STAT3 but appear to do so through different modules, perhaps
localized to different cell types.
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Introduction
Astrogliosis, the ‘‘reactive’’ state of astrocytes, is a pathological
hallmark of all types of CNS injuries [1–5]. A dominant feature of
astrogliosis is cellular hypertrophy with an attendant accumulation
of GFAP-enriched intermediate filaments [3,6,7]. Different types
of injuries and multiple molecular signaling pathways are able to
trigger this common feature of astrocytic reactivity. Nevertheless, a
wide spectrum of potential molecular and cellular features of
astrogliosis also have been described [8,9]; qualitatively dissimilar
insults of varying severity (e.g., neurodegenerative disease,
neurotrauma or neurotoxicity) may engender varying degrees of
astrogliosis with different morphological features, molecular
underpinnings and functional consequences [8–10]. Thus, focus-
ing on limited numbers of injury models to investigate astrogliosis
may lead to generalizations that do not apply to all types of
astroglial responses to injury.
Here we examined signaling events associated with astrocytic
responses to neural damage resulting from diverse neurotoxic
insults. Using neurotoxicants to instigate astrogliosis is advanta-
geous because different brain regions and often, different cell types
within a given region, can be selectively targeted. Previously, we
found that different neurotoxicants result in brain-region-specific
astrogliosis tightly linked to the damaged target, as well as the
dose, time and duration of the neurotoxic effect, regardless of the
region or cell type affected [11]. Because systemic administration
of these neurotoxicants often does not damage the blood-brain
barrier (BBB), the observed astroglial responses are not compli-
cated by contribution of blood-borne factors at the sites of damage,
as is the case for other models. Moreover, pharmacological and
genetic manipulations of neurotoxicity reveal that neurotoxic
injuries of neuronal targets serve as the stimulus to initiate
astrogliosis, thereby ruling out direct effects on the astrocytes
themselves. Using diverse neurotoxicity models to delineate
common signaling mechanisms responsible for instigating astro-
gliosis offers an approach for pursuit of therapeutic interventions
based on manipulating astroglial reactivity.
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Previously, we showed that MPTP-induced dopaminergic
neurotoxicity was linked to rapid but transient phosphorylation
of STAT3Tyr 705, and its translocation to astrocytic nuclei, prior to
the induction of GFAP mRNA and protein [12]. Enhanced
expression of proinflammatory signaling through the JAK2-
STAT3 pathway was observed prior to onset of STAT3 activation.
Other proinflammatory mediators known to feed into the JAK-
STAT3 signaling cascade (e.g., TNF-a and IL-1b) [13] also
showed enhanced expression prior to phosphorylation of STAT3
and induction of GFAP [14]. These findings suggested that
neuroinflammation-mediated activation of the STAT3 pathway
may be associated with induction of astrogliosis, findings consistent
with prior observations for a role of STAT3 in astroglial reactivity
and scar formation resulting from neurotrauma and ischemia [15–
19]. Here we sought to determine the role of enhanced astrocytic
STAT3 signaling in multiple mechanistically distinct models of
neurotoxicity. Because proinflammatory signaling in the CNS can
occur in the absence of neural damage [20–23] we also examined
whether such neuroinflammatory responses could activate STAT3
without inducing astrogliosis. While our findings strongly implicate
astroglial STAT3 activation as a common feature in all of our
neurotoxicity models, we also observed that acute neuroinflam-
matory responses to the known inflammogen, LPS, can activate
STAT3 without inducing GFAP up-regulation, a hallmark of
astrogliosis. Thus, acute phase neuroinflammatory responses and
neurotoxicity-induced astrogliosis signal through STAT3 but
appear to do so through different STAT3 modules.
Materials and Methods
The following drugs and chemicals were kindly provided by or
obtained from the sources indicated: lipopolysaccharide (LPS;
Sigma Chemical Co., St. Louis, MO), 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP; Aldrich, Milwaukee, WI), metham-
phetamine (METH; Sigma), amphetamine (AMP; Sigma), 3,4-
methylenedioxymethamphetamine (MDMA; Research Technolo-
gy Branch of the National Institute on Drug Abuse, Rockville,
MD), 3,4-methylenedioxyamphetmine (MDA; Research Technol-
ogy Branch of the National Institute on Drug Abuse), kainic acid
(KA; Sigma), trimethyltin (TMT; K&K Laboratories, Division of
ICN Biochemical, Cleveland, OH), nomifensine (Sigma), Ethanol
(Sigma), diazepam (Sigma), minocycline (Sigma), corticosterone
(CORT; Steraloids, Inc., Newport, RI), bicinichoninic acid
protein assay reagent and bovine serum albumin (Pierce Chemical
Co., Rockford, IL). The materials used in the glial fibrillary acidic
protein (GFAP) ELISA have been described in detail [24,25]. The
materials used in the tyrosine hydroxylase (TH) ELISA have been
described previously [12,26,27]. All other reagents and materials
were of at least analytical grade and were obtained from a variety
of commercial sources.
Animals
Studies on MPTP, METH, AMP, MDMA, MDA and TMT
used male C57BL/6J mice; studies on KA used male FVB/NJ
mice; LPS studies used female C57BL/6J mice. An additional
study on TMT used male Long-Evans rats where indicated.
Figure 1. STAT3 activation precedes GFAP up regulation in multiple models of striatal neurotoxicity. Mice were administered
dopaminergic neurotoxicants, MPTP, AMP, METH, MDA and MDMA with saline (0.9%) as a control and were killed at 6, 12 and 72 hours post dosing,
time points known to encompass the onset of dopaminergic neurotoxicity and the subsequent activation of microglia and astroglia [12]. Mice were
killed by focused microwave irradiation to preserve steady-state phosphorylation of pSTAT3tyr 705 and phosphorylation was analyzed by
quantification of scans of pSTAT3tyr705 immunoblots. Representative immunoblot data from two different animals killed at each time point are
presented above the quantitative data obtained from scans and are denoted by a bracket. Separate groups of mice were used to prepare total RNA
from one side of the brain for qRT-PCR analysis of Gfap mRNA and to prepare total protein homogenates from the other side of the brain for ELISA of
GFAP and TH. Except for the representative immunoblot duplicates, all data points represent mean 6 SEM, N=5. Statistical significance was
measured by one-way ANOVA with Fisher’s LSD Method of post hoc analysis. Statistical significance of at least p,0.05 for the neurotoxicant exposed
groups in comparison to saline controls is denoted by *. See Methods for dosing regimen (multi-dose METH).
doi:10.1371/journal.pone.0102003.g001
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C57BL/6J or FVB/NJ mice (n = 5 mice per group) 4–6 weeks of
age were purchased from Jackson Labs (Bar Harbor, ME). Long-
Evans male rats were purchased from Charles River Laboratories
International, Inc. (Wilmington, MA).
Mice selectively deficient in STAT3 in astrocytes (STAT3-
CKO) using GFAP promoter-directed Cre/loxP technology as
described previously [17,28] were used for GFAP and TH protein
quantification after MPTP exposure.
All procedures were performed within protocols approved by
the Institutional Animal Care and Use Committee of the Centers
for Disease Control and Prevention, National Institute for
Occupational Safety and Health, and the animal colony was
certified by the American Association for Accreditation of
Laboratory Animal Care. Upon receipt, male mice were housed
individually and females were housed in groups of 6 in a
temperature-controlled (2161uC unless otherwise stated) and
humidity-controlled (50610%) colony room maintained under
filtered positive-pressure ventilation on a 12 h light/12 h dark
cycle beginning at 0600 EDT. The plastic tub cages were 46 cm in
length by 25 cm in width by 15 cm in height; cage bedding
consisted of heat-treated pine shavings spread at a depth of
approximately 4 cm. Food (Purina rat/mouse chow) and water
were available ad libitum.
Dosing
Neurotoxicants were administered to mice as follows: MPTP
(12.5 mg/kg, s.c.), AMP (10 mg/kg, s.c., 3 injections at 2 h
intervals), METH (20 mg/kg, s.c., 3 injections at 2 h intervals
(specified as multi-dose in appropriate figure legends) or a single
dose of 20 mg/kg, s.c. (specified as single dose in appropriate
figure legends), MDA (10 mg/kg, s.c., 3 injections at 2 h intervals),
MDMA (20 mg/kg, s.c., 3 injections at 2 h intervals), KA (20 mg/
kg, s.c.) and TMT (0.5 mg/kg, i.p.). TMT was administered to rats
at a dosage of 8.0 mg/kg, i.p. All dosages were administered as the
base compound.
Pharmacologic and environmental manipulations were admin-
istered to mice as follows: Nomifensine (25 mg/kg, s.c.) was given
30 min before MPTP, Ethanol (3 g/kg, s.c.) was given 30 min
Figure 2. STAT3 Activation precedes GFAP up regulation in diverse models of damage affecting different brain areas. Mice were
administered the hippocampal neurotoxicant KA and mice and rats were administered the hippocampal neurotoxicant, TMT. Mice were killed by
focused microwave irradiation to preserve steady-state phosphorylation of pSTAT3tyr 705 and phosphorylation was analyzed by quantification of
scans of pSTAT3tyr705 immunoblots. Representative immunoblot data from two different animals killed at each time point are presented above the
quantitative data obtained from scans and are denoted by a bracket. Separate groups of mice were used to prepare total RNA from one side of the
brain for qRT-PCR analysis of Gfap mRNA and to prepare total protein homogenates from the other side of the brain for ELISA of GFAP. Except for the
representative immunoblot duplicates, all data points represent mean 6 SEM, N= 5 (with the exception of pSTAT3 expression in TMT treated mice in
which N=2). Statistical significance was measured by one-way ANOVA with Fisher’s LSD Method of post hoc analysis. Statistical significance of at
least p,0.05 for the neurotoxicant exposed groups in comparison to saline controls is denoted by *. See Methods for dosing regimen.
doi:10.1371/journal.pone.0102003.g002
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Figure 3. STAT3 Activation is localized to astrocytes after hippocampal as well as striatal neurotoxicity. Mice were administered METH
or KA and were processed for immunohistochemical analyses of GFAP to identify astrocytes (denoted by arrows) and STAT3. GFAP immunostaining
revealed hypertrophied striatal astrocytes at 12 hours after METH and were further evident by 72 hours. STAT3 staining of striatal nuclei indicative of
its translocation and, therefore, activation, was apparent at 72 hours; STAT3 activation was localized to astrocytes as evidenced by an increase in
nuclear stating in the merged images at 12 and 72 hours. STAT3 and GFAP staining were not evident in saline-treated striatum sections. In the
hippocampus, GFAP immunostaining revealed astrocytes in saline-treated mice; enhanced immunostaining of astrocytes was evident by 72 hours
after administration of KA. STAT3 staining of nuclei in hippocampus was prominent at 12 and 72 hours after KA but not evident in saline controls;
merging of GFAP and STAT3 images showed increased nuclear staining of GFAP positive cells at 12 and 72 hours post KA suggestive of the
translocation of and activation of STAT3 in astrocytes. Merge of GFAP and STAT3 is shown with DAPI for clarity of nucleus location. Arrows
corresponding to GFAP positive astrocytes are included in each panel to focus on the points of interest. Scale bars = 20 mm. See Methods for dosing
regimens.
doi:10.1371/journal.pone.0102003.g003
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before METH (20 mg/kg, s.c.), Diazepam (30 mg/kg, i.p.) was
given 30 min before KA, and CORT (20 mg/kg, s.c.) was given
30 min prior to MPTP, METH, TMT or LPS. Mice were kept at
15uC for 24 hours and then treated with METH (20 mg/kg, s.c.)
and kept at 15uC until killed.
LPS was used as a known inflammogen and administered at a
dosage of 2 mg/kg, s.c. or, in the dose-response experiment, at a
dosage of 1–5 mg/kg, i.p. [5].
The post-dosing time points were chosen to capture peak
expression of cytokines (6–12 hrs.), pSTAT3 (12 hrs) and GFAP
(12–72 hrs) based on our previous findings for MPTP [12],
substituted amphetamines [29], LPS (unpublished data) and our
historical data for induction of GFAP on all compounds used (e.g.,
see [30]).
Brain dissection and tissue preparation
Mice were killed by decapitation and whole brains were
removed from the skull with the aid of blunt curved forceps.
Striatum, hippocampus, cortex, cerebellum and olfactory bulb
were dissected free hand on a thermoelectric cold plate (Model
TCP-2, Aldrich Chemical Co., Milwaukee, WI) using a pair of fine
curved forceps (Roboz, Washington, DC). Brain regions from one
side of the brain were frozen at -85uC and used for subsequent
isolation of total RNA; brain regions from the other side of the
brain were used for total and specific protein analysis. The right-
side brain regions were weighed, homogenized with a sonic probe
(model XL-2005, Heat Systems, Farmingdale, NY) in 10 volumes
of hot (90–95uC) 1% sodium dodecyl sulfate, and stored frozen at
270uC before total protein assay and immunoassay of GFAP and
TH.
A separate set of mice were used for pSTAT3tyr 705
quantification and were killed by focused microwave irradiation
(Muromachi Kikai, Inc., Tokyo, Japan; Model TMW-4012C, 3.5
KW applied power, 0.90 sec) to preserve steady-state protein
phosphorylation [31]. Brains were dissected freehand, weighed
and homogenized in 10 volumes of hot 1% SDS and then stored at
280uC until assayed. We note that while this mode of sacrifice
may be essential for preservation of phosphorylation of many
phosphoproteins [31,32], pSTAT3tyr 705 can successfully be
preserved by rapid decapitation and sample denaturation in hot
1% SDS [31].
For immunohistochemistry experiments, animals were transcar-
dially perfused with saline (0.9%) followed by formalin (10%) to fix
the brain tissue. Brains were removed and kept in formalin (10%)
until embedded in paraffin. Tissue was cut and placed in Paraform
cassettes (Sakura Finetek, Torrance, CA) for subsequent process-
ing by dehydration, clearing and infiltration overnight with
paraffin using a Tissue-Tek VIP 5 Vacuum Infiltration Processor
(Sakura Finetek). Briefly, the brains were processed in 10%
formalin, 70%, 80%, 95% and 100% ethanol, xylene and then
paraffin. The cassette with paraffin-embedded tissue was then
attached to a mold (Sakura Finetek) with paraffin.
RNA isolation, cDNA synthesis, and real-time PCR
amplification
Total RNA from striatum, hippocampus, cortex, cerebellum
and hypothalamus were isolated using Trizol reagent (Invitrogen,
Grand Island, NY) and Phase-lock heavy gel (Eppendorf AG,
Hamburg, Germany). The RNA was further cleaned using
RNeasy mini spin column (Qiagen, Valencia, CA). Total RNA
Figure 4. STAT3 Activation does not occur in non-damaged brain regions in multiple models of neurotoxicity. Mice were administered
METH, KA or TMT with saline (0.9%) as a control and were killed by focused microwave irradiation at 12 hrs. post dosing and by decapitation at
72 hours post dosing. Multiple ‘‘non-target’’ brain regions for each neurotoxicant were sampled for activated STAT3 (12 hours post dosing) and levels
of GFAP (72 hours post dosing). All data points represent mean 6 SEM, N= 5. Statistical significance was measured by one-way ANOVA. Where
significant differences were found, Fisher’s LSD Method of post hoc analysis was performed. Statistical significance of at least p,0.05 for the
neurotoxicant exposed groups in comparison to saline controls is denoted by *. See Methods for dosing regimen (multi-dose METH).
doi:10.1371/journal.pone.0102003.g004
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(1 mg) was reverse transcribed to cDNA using SuperScript II
RNase H2 and oligo (dT)12-18 primers (Invitrogen) in a 20 mL
reaction. Real-time PCR analysis of Glyceraldehyde-3-phosphate
dehydrogenase (Gapdh), tumor necrosis factor-alpha (Tnf-a),
chemokine (C-C motif) ligand 2 (Ccl2), Leukemia inhibitor factor
(Lif), Oncostatin M (Osm) and glial fibrillary acidic protein (Gfap)
was performed in an ABI PRISM 770 sequence detection system
(Applied Biosystems, Carlsbad, CA) in combination with TaqMan
chemistry. Specific primers and dual-labeled internal fluorogenic
(FAM/TAMRA) probe sets (TaqMan Gene Expression Assays) for
these genes were procured from Applied Biosystems and used
according to the manufacturer’s recommendations. All PCR
amplifications (40 cycles) were performed in a total volume of
50 mL, containing 1 mL cDNA, 2.5 mL of the specific Assay of
Demand primer/probe mix, and 25 mL of Taqman Universal
master mix. Sequence detection software (version 1.7; Applied
Biosystems) results were exported as tab-delimited text files and
imported into Microsoft Excel for further analysis. Relative
quantification of gene expression was performed using the
comparative threshold (CT) method as described by the manufac-
turer (Applied Biosystems; User Bulletin 2). Changes in mRNA
expression levels were calculated after normalization to Gapdh.
The ratios obtained after normalization are expressed as fold
change over corresponding saline-treated controls.
Protein assay
Total protein was determined by the bicinchoninic acid method
[33] using bovine serum albumin as standard.
GFAP and TH assays
GFAP was assayed in accordance with a previously described
ELISA [24,25]. In brief, a rabbit polyclonal antibody to GFAP
(1:300; DAKO, Carpenteria, CA) was coated on the wells of
Immulon-2 microliter plates (Thermo Labsystems, Franklin, MA).
The sodium dodecyl sulfate homogenates and standards were
diluted in phosphate-buffered saline (pH 7.4) containing 0.5%
Triton X-100. After blocking non-specific binding with 5% non-fat
dairy milk, aliquots of the homogenate and standards were added
to the wells and incubated. Following washes, a mouse monoclonal
antibody to GFAP (1:200; EMD Millipore-Calbiochem, Billerica,
MA) was added to ‘sandwich’ the GFAP between the two
antibodies. An alkaline phosphatase-conjugated antibody directed
against mouse IgG (1:2000; Jackson ImmunoResearch, West
Grove, PA) was then added and a colored reaction product was
obtained by subsequent addition of the enzyme substrate p-
nitrophenol (Bio-Rad Laboratories, Hercules, CA). Quantification
was achieved by spectrophotometry of the colored reaction
product at 405 nm in a microplate reader, Spectra Max Plus,
Figure 5. STAT3 activation, like GFAP up regulation, results from damage associated with multiple models of neurotoxicity:
evidence from neuroprotective agents. Mice were administered MPTP, METH, or KA alone or after pretreatment with nomifensine (for MPTP),
ethanol or low ambient temperature (for METH) or diazepam (for KA). Mice were killed at 12 hours post dosing by focused microwave irradiation for
analyses of pSTAT3tyr 705 by quantitative immunoblotting or were killed by decapitation at 72 hours post dosing for analyses of GFAP and TH by
ELISA. Striatal samples were assayed after MPTP and METH and hippocampal samples were assayed after KA. Representative immunoblot data from
two different animals for each treatment condition are presented above the quantitative data obtained from scans. Except for the representative
immunoblot duplicates, all data points represent mean 6 SEM, N=5. Statistical significance was measured by two-way ANOVA with Fisher’s LSD
Method of post hoc analysis. * denotes statistical significance of at least p,0.05 for the neurotoxicant alone or pretreated groups compared to saline
controls and # denotes statistical significance of at least p,0.05 for neuroprotectant pretreated groups compared to neurotoxicant only exposed
groups. See Methods for dosing regimen (single dose METH).
doi:10.1371/journal.pone.0102003.g005
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and analyzed using Soft Max Pro Plus software (Molecular
Devices, Sunnyvale, CA). The amount of GFAP in the samples
was calculated as micrograms of GFAP per milligram total
protein.
TH holoenzyme protein was assessed using a fluorescence-based
ELISA developed in the laboratory [12]. The protocol was
essentially similar to that for the GFAP assay except that a mouse
monoclonal antibody to TH (1:400; Sigma-Aldrich, St. Louis) was
used as the plate capture antibody and a rabbit polyclonal
antibody (EMD Millipore-Calbiochem, Billerica, MA) was used to
‘sandwich’ TH protein. The amount of sandwich antibody bound
to TH was then detected using a peroxidase-labeled antibody
directed against rabbit IgG (Artisan Technology Group, Cham-
paigne, IL). Peroxidase activity was detected using the fluorogenic
substrate Quantablu (Pierce), which has excitation and emission
maxima of 325 and 420 nm, respectively (read at 320/405 nm).
The amount of TH in the samples was calculated and expressed as
micrograms TH per milligram total protein.
pSTAT3 immunoblot analysis
Activation of the STAT3 pathway was assessed by quantifying
pSTAT3tyr705 using immunoblot analysis with detection of
fluorescent signals using an infrared fluorescence scanner (Licor
Biosciences, Lincoln, NE) or with detection using an ECL
chemiluminescent substrate (Amersham Biosciences, Piscataway,
NJ) captured onto x-ray film (Fuji Medical systems, Stamford, CT)
as described previously [12,19]. Briefly, following incubation with
primary antibodies (anti-phospho-STAT3tyr705[1:500]), blots were
washed with phosphate buffered saline with 0.1% Tween 20 and
incubated with fluorescent-labeled secondary antibodies (1:2500)
for 1 h prior to scanning by Licor or using a Personal
Densitometer (Molecular Dynamics, Sunnyvale, CA).
Histology
For immunohistochemical analysis of STAT3 and GFAP the
paraffin embedded brains were sectioned with a manual rotary
Microm microtome (Thermo Scientific, Kalamazoo, MI) into
6 mm sections and floated onto Superfrost + slides (Fisher
Scientific). The slides were warmed at 60uC for 20 min. To
dissolve away the paraffin, slides were put through xylene and then
100% followed by 95% ethanol washes. Following an overnight
incubation in primary antibody STAT3 (rabbit;1:300; Cell
Signaling Technology, Inc., Danvers, MA); GFAP (chicken;1:300;
Abcam, Cambridge, MA) sections were rinsed in PBS and
incubated with secondary antibody (for STAT3, 1:250; for GFAP
1:250) for 4 hours at room temperature. The sections were rinsed
and coverslipped with prolong gold antifade with DAPI mountant
(Life Technologies, Grand Island, NY). The sections were
visualized using an Olympus AX70 microscope with a PlanApo
40x 0,85 NA objective lens and images captured using Cell Sens
Dimension software with the Olympus DP73 digital camera
attached to the microscope. Post-processing of images was done
according to accepted practices and image integrity guidelines
(e.g., [34,35]). Specifically, the tone was normalized in all images
and STAT3 images were sharpened.
Statistics
All analyses were performed using SigmaPlot (version 11)
statistical software. The test of significance was performed using
either one or two way ANOVA followed by Fisher LSD test of log
transformed data. Values were considered statistically significant at
5% level of significance (p,0.05). Graphical representations are
mean 6 SEM.
Results
STAT3 activation coincides with the onset of damage and
precedes GFAP up regulation in multiple models of
striatal neurotoxicity
Using the known dopaminergic neurotoxicant, MPTP, as a
chemical denervation tool, we previously demonstrated that
activation of the JAK2/STAT3 pathway in astrocytes, in vivo,
precedes the up regulation of the astrocyte intermediate filament
protein, GFAP, a hallmark of astrogliosis [12]. If the JAK2/
STAT3 pathway is a key to induction of astrogliosis, then like
astrogliosis, phosphorylation of STAT3tyr705 should be associated
with multiple models of CNS neurotoxicity. To assess this
possibility we began by examining the time-course of STAT3
phosphorylation in relation to the expression of GFAP following
the administration of multiple neurotoxic insults known to damage
dopaminergic nerve terminals in the striatum (Fig. 1). In
agreement with our prior findings, MPTP resulted in a time-
Figure 6. Conditional deletion of STAT3 blocks neurotoxicant-
induced GFAP up regulation. Wild type (C57), Stat3 (+/+) or Stat3
(2/2) mice were administered MPTP (12.5 mg/kg, s.c.) and killed at 12
and 72 hours post dosing. Striatal GFAP and TH were measured by
ELISA. All data points represent mean 6 SEM, N= 5. Statistical
significance was measured by two-way ANOVA with Fisher’s LSD
Method of post hoc analysis. Statistical significance of at least p,0.05
for the MPTP-exposed groups is denoted by * as compared to wild-type
controls (C57) and by # as compared to the wild-type (C57) and
Stat3+/+ groups.
doi:10.1371/journal.pone.0102003.g006
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dependent decrease in striatal TH consistent with the loss of
dopaminergic terminals. Coincident with this nerve terminal
damage, STAT3 was activated by phosphorylation on Tyr 705,
followed by the induction of Gfap mRNA, and the enhanced
expression of GFAP. Amphetamine and a series of its substitutes
(METH, MDA, and MDMA), all also known to damage
dopaminergic terminals in the mouse [29,36], showed the same
relationship among loss of TH, activation of STAT3, and
induction of GFAP (mRNA and protein). Dexfenfluramine, an
amphetamine that does not damage the striatum [29,36], did not
activate STAT3 or induce the expression of GFAP (data not
shown). Non-phospho STAT3 levels were not affected by these
dopaminergic neurotoxicants.
STAT3 activation precedes GFAP up regulation in diverse
models of damage affecting multiple brain areas
If activation of STAT3 represents a signaling mechanism
common to astrogliosis, it should occur in any of the brain regions
damaged by the varied types of neurotoxic insults. To address this
issue we administered neurotoxicants known to damage the
hippocampus and cause an ensuing astrogliosis (Fig. 2). We found
that the excitotoxic compound, KA, as well as the organotin
neurotoxicant, TMT, resulted in an enhanced expression of GFAP
preceded by activation of STAT3 in hippocampus. TMT causes
hippocampal damage in both mice and rats and we observed
enhanced expression of GFAP preceded by activation of STAT3
in the rat, and a trend toward activation of STAT3 in the mouse
that did not reach significance, likely due to a low N. Collectively,
these data show that phosphorylation of STAT3tyr 705 is associated
with the induction of astrogliosis in multiple models of neurotox-
icity affecting different brain regions and causing damage via
different mechanisms. As with the dopaminergic neurotoxicants,
the increases in phospho-STAT3tyr 705 could not be attributed to
increases in STAT3.
STAT3 activation is localized to astrocytes after striatal
and hippocampal neurotoxicity
Previously, we showed that damage to dopaminergic nerve
terminals from a single dose of the dopaminergic neurotoxicant,
MPTP, resulted in striatal-selective increases in GFAP and
activation of STAT3 localized to astrocytes. Here we determined
if astrocytic localization of STAT3 also would be associated with
the astrocytic response to METH-induced dopaminergic neuro-
toxicity in striatum and KA-induced neurotoxicity in hippocampus
(Fig. 3). Damage to dopaminergic nerve terminals in striatum by a
single 20 mg/kg dose of METH resulted in enhanced immuno-
staining of GFAP (denoted by arrows), consistent with astrogliosis
and the previously documented increases in striatal GFAP
[27,29,37]. Enhanced GFAP staining was detected as early as
12 hours after METH. STAT3 immunostaining was used to
gauge translocation and enrichment of nuclear STAT3 in
astrocytes [12]. Merging of GFAP and STAT3 and GFAP and
STAT3 with DAPI immunostaining showed enhanced nuclear
and perinuclear staining at both 12 and 72 hours after METH.
STAT3 staining alone showed localization to the nucleus by
72 hours after METH. As with the damage to striatum
engendered by MPTP and amphetamines, damage to hippocam-
pus by a single 20 mg/kg dose of KA resulted in enhanced
immunostaining of GFAP (denoted by arrows; Fig. 3) consistent
with the previously documented increase in hippocampal GFAP
(Fig. 2). Enhanced GFAP immunostaining was observed as early as
12 hours after KA and increased by 72 hours after KA. Merging
of GFAP and STAT3 and GFAP and STAT3 with DAPI
immunostaining showed enhanced nuclear staining localized to
astrocytes that appeared to increase between 12 and 72 hours after
Figure 7. STAT3 activation is preceded by enhanced expression of proinflammatory ligands in multiple models of neurotoxicity.
Mice were administered MPTP, AMP, METH, MDA, MDMA, KA and TMT with saline (0.9%) as a control and were killed at 6, 12 and 72 hours post
dosing. Total RNA was prepared from striatum (MPTP, AMP, METH, MDA and MDMA) or hippocampus (KA and TMT) for qRT-PCR analysis of Tnf-a,
Osm, Ccl2 or Lif. All data points represent mean 6 SEM, N= 5. Statistical significance was measured by one-way ANOVA with Fisher’s LSD Method of
post hoc analysis. Statistical significance of at least p,0.05 for the neurotoxicant exposed groups in comparison to saline controls is denoted by an
asterisk. See Methods for dosing regimen (multi-dose METH).
doi:10.1371/journal.pone.0102003.g007
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KA. STAT3 staining alone was largely nuclear and was most
apparent at 72 hours after administration of KA. STAT3
immunostaining was not observed in saline controls for striatum
or hippocampus. Together, these observations are consistent with
an astrocytic localization of activated STAT3 in association with
the induction of astrogliosis.
STAT3 activation does not occur in non-damaged brain
regions in multiple models of neurotoxicity
Toxicant-induced astrogliosis is restricted to the onset, duration,
and location of damage [11]. Therefore, areas of the CNS not
affected by a given neurotoxic exposure do not show astrogliosis.
Previously we have shown that activation of STAT3 and
astrogliosis due to MPTP-induced dopaminergic neurotoxicity is
restricted to the striatum and non-target regions of the brain
remain unaffected [12]. In agreement with the findings for MPTP,
brain regions not damaged by METH, KA, and TMT in our
mouse models, based on other indices of damage such as Fluoro-
Jade staining and argyrophilia ([38]; data not shown), did not show
an activation of STAT3 or induction of GFAP (with the exception
of a few very minor statistically significant changes) (Fig. 4). These
observations provide a further link to the activation of STAT3 as
an early biomarker of astrogliosis.
STAT3 activation, like GFAP up regulation, results from
damage associated with multiple models of
neurotoxicity: evidence from neuroprotective agents
If activation of STAT3, like astrogliosis, is linked to damage,
then neuroprotective agents that prevent damage should prevent
the activation of STAT3 and astrogliosis. Preventing MPP+ access
to striatal dopaminergic nerve terminals by pretreatment with the
dopamine transporter antagonist, nomifensine, is known to protect
against MPTP-induced dopaminergic neurotoxicity. In agreement
with our previous findings [12], pretreatment with nomifensine
prevented the activation of STAT3, induction of astrogliosis (as
measured by increases in GFAP levels) and the dopaminergic
neurotoxicity (decrease in TH) associated with MPTP-induced
neurotoxicity (Fig. 5). Lowering core temperature by prior
treatment with ethanol or by lowering ambient temperature is
known to protect against METH-induced neurotoxicity [36].
These interventions prevented the activation of STAT3, the
induction of astrogliosis and dopaminergic neurotoxicity due to
METH (Fig. 5). Diazepam can block or attenuate neurotoxicity
due to kainate [39]. Pretreatment with diazepam (30 mg/kg, i.p.)
blocked kainate-induced activation of STAT3 and markedly
attenuated kainate-induced astrogliosis (Fig. 5). Together, these
observations indicate that activation of STAT3, like the induction
Figure 8. Enhanced expression of proinflammatory ligands results from neurotoxicity-induced damage: evidence from
neuroprotective agents. Mice were administered MPTP, METH, or KA alone or after pretreatment with nomifensine (for MPTP), ethanol (for
METH) or diazepam (for KA). Mice were killed at 12 hours post dosing. Total RNA was prepared from striatum (MPTP and METH) or hippocampus (KA)
for qRT-PCR analysis of Tnf-a, Osm, Ccl2 or Lif. All data points represent mean6 SEM, N= 5. * denotes statistical significance of at least p,0.05 for the
neurotoxicant alone or pretreated groups compared to saline controls and # denotes statistical significance of at least p,0.05 for neuroprotectant
pretreated groups compared to neurotoxicant only exposed groups. Statistical significance was measured by two-way ANOVA with Fisher’s LSD
Method of post hoc analysis. See Methods for dosing regimen (single dose METH). Data for Osm and Lif in the MPTP groups was taken from Fig. 8 in
Sriram et al., (2004) [12].
doi:10.1371/journal.pone.0102003.g008
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of astrogliosis, results from neuronal damage caused by multiple
mechanistically diverse neurotoxicants that damage different
regions of the brain.
Conditional deletion of STAT3 blocks neurotoxicant-
induced GFAP up regulation
Data presented in the previous figures provide a correlational
implication for a role of STAT3 in the induction of astrogliosis. If
STAT3 signaling plays a causal role in neurotoxicant-induced
astrogliosis, then its ablation in astrocytes by conditional gene
deletion should block the astroglial response to neurotoxic insult.
Using the same STAT3 conditional knock-out (CKO) mice
previously shown to attenuate the up regulation of GFAP and
associated astrogliosis in a spinal cord injury model [17], we found
that basal expression of GFAP in striatum was attenuated and the
enhanced expression of GFAP in response to MPTP-induced
dopaminergic neurotoxicity was markedly attenuated (Fig. 6). The
lack of an induction of GFAP in response to MPTP was unlikely to
be related to an effect of the conditional STAT3 deletion on
MPTP-related dopaminergic neurotoxicity because tyrosine hy-
droxylase, a marker of dopaminergic nerve terminals in striatum,
was decreased to the same degree in CKO mice treated with
MPTP.
STAT3 activation is preceded by enhanced expression of
proinflammatory ligands upstream of JAK2/STAT3 in
multiple models of neurotoxicity
It is well known that cytokines can activate the JAK2/STAT3
pathway (see reviews: [40,41]). Up regulation of gp130-and related
cytokines associated with the activation of the JAK2/STAT3
pathway precedes activation of STAT3 and astrogliosis in the
MPTP model of neurotoxicity [12]. These prior observations were
suggestive of a signaling role of proinflammatory cytokines in
mediating or modulating the induction of astrogliosis. Here we
evaluated proinflammatory cytokine/chemokine expression pro-
files associated with other models of striatal neurotoxicity and
determined if similar responses would be observed with hippo-
campal neurotoxicity models. Rapid and large-fold up regulation
of Tnf-a, Osm, Ccl2 and Lif were confirmed for MPTP and
METH neurotoxicity exposures (Fig. 7). In addition to METH,
AMP and its substitutes, MDA and MDMA, also caused the rapid
induction of these same proinflammatory signals. The time course
of these signaling events preceded the time course for activation of
STAT3 and the induction of Gfap mRNA and GFAP protein (see
Fig. 1). Similarly, the hippocampal neurotoxicants, KA and TMT,
also resulted in enhanced expression of mRNA for the same
cytokines/chemokines (Fig. 7), prior to the onset of the activation
of STAT3 and the induction of Gfap mRNA or GFAP protein
(Fig. 2). Together, these data indicate that mechanistically diverse
neurotoxic exposures damaging two different brain regions all
result in the enhanced expression of proinflammatory cytokines
upstream of STAT3 prior to induction of GFAP and associated
astrogliosis.
Figure 9. Anti-inflammatory treatment with CORT suppresses enhanced expression of proinflammatory ligands in multiple models
of neurotoxicity.Mice were administered MPTP, METH, or TMT alone or after pretreatment with CORT (20 mg/kg, s.c.) 30 minutes earlier. Mice were
killed at 12 hours post dosing. Total RNA was prepared from striatum (MPTP and METH) or hippocampus (TMT) for qRT-PCR analysis of Tnf-a, Osm,
Ccl2 or Lif. All data points represent mean 6 SEM, N= 5. * denotes statistical significance of at least p,0.05 for the neurotoxicant alone or CORT
pretreated groups compared to saline controls and # denotes statistical significance of at least p,0.05 for CORT- pretreated groups compared to
neurotoxicant only exposed groups. Statistical significance was measured by two-way ANOVA with Fisher’s LSD Method of post hoc analysis. See
Methods for dosing regimen (single dose METH).
doi:10.1371/journal.pone.0102003.g009
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Enhanced expression of proinflammatory ligands results
from damage associated with multiple models of
neurotoxicity: evidence from neuroprotective agents
If enhanced expression of proinflammatory cytokines/chemo-
kines upstream of STAT3 is linked to damage, then neuroprotec-
tive agents that prevent damage should prevent enhanced
expression of these proinflammatory mediators, as well as
activation of STAT3 and astrogliosis. To address this question,
we again used nomifensine, ethanol and diazepam to protect
against MPTP, METH and KA neurotoxicity, respectively (Fig. 8).
Pretreatment with nomifensine and ethanol completely blocked
the enhanced expression of Tnf-a, Osm, Lif and Ccl2 associated
with MPTP and METH neurotoxicity, respectively. Diazepam
blocked the expression of Osm in the KA neurotoxicity model. Lif
was not affected by diazepam in the KA model. While these data,
in general, are consistent with a relationship among the expression
of proinflammatory mediators and damage resulting from MPTP,
METH and KA, the lack of significant protection by diazepam
against KA induced expression of Tnf-a and Ccl2 demonstrate a
lack of complete concordance. Moreover, the complete lack of
protection of diazepam against expression of Lif in the KA model
is not consistent with the at least partial protection of diazepam
against KA-induced activation of STAT3 and elevation in GFAP
(Fig. 5), i.e. the diazepam protection data for KA may indicate that
the proinflammatory response can be separated from the damage
response. Data for nomifensine neuroprotection against induction
of Osm and Lif in the MPTP model were taken from Sriram et al.,
(2004) [12].
Anti-inflammatory treatment with CORT suppresses the
enhanced expression of proinflammatory ligands
upstream of STAT3 in multiple models of neurotoxicity
Because neuroprotective agents that block or suppress neuro-
toxicity due to MPTP, METH, and KA also block or suppress the
enhanced neuroinflammatory effects associated with these agents,
it follows that neuroinflammatory mediators upstream of STAT3
play a role in neurotoxicant-induced damage. To begin to
examine this issue, we determined if the classic species-specific
anti-inflammatory glucocorticoid, CORT, would suppress the
neuroinflammatory response associated with diverse neurotoxic
exposures (Fig. 9). CORT (20 mg/kg, s.c.) administered 30
minutes prior to MPTP, METH or TMT suppressed the
expression of Tnf-a, Osm, Ccl2 and Lif associated with the
neurotoxic effects of these agents. These data suggested that the
acute dosage of CORT had the desired anti-inflammatory effect
on neurotoxicant-associated neuroinflammation.
Figure 10. Anti-inflammatory treatment with CORT does not suppress activation of STAT3, GFAP expression, or neurotoxicity. Mice
were administered MPTP, METH, or TMT alone or after pretreatment with CORT (20 mg/kg, s.c.) 30 minutes earlier and killed at the post-dosing times
indicated. Mice were killed by focused microwave irradiation to preserve steady-state phosphorylation of pSTAT3tyr 705 and striatal phosphorylation
was analyzed by quantification of scans of pSTAT3tyr705 immunoblots. Representative immunoblot data from two different animals for each dosing
groups are presented above the quantitative data obtained from scans. Separate groups of mice killed by decapitation were used to prepare total
striatal protein homogenates for ELISA of GFAP and TH. All data points represent mean 6 SEM, N=5. * denotes statistical significance of at least p,
0.05 for the neurotoxicant alone or CORT pretreated groups compared to saline controls and # denotes statistical significance of at least p,0.05 for
CORT- pretreated groups compared to neurotoxicant only exposed groups. Statistical significance was measured by two-way ANOVA with Fisher’s
LSD Method of post hoc analysis. See Methods for dosing regimens (single dose METH).
doi:10.1371/journal.pone.0102003.g010
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Anti-inflammatory treatment with CORT does not
suppress activation of STAT3, GFAP up regulation, or
neurotoxicity
To determine if suppression of the neuroinflammatory respons-
es associated with MPTP, METH, and TMT neurotoxicity
suppressed activation of STAT3, astrogliosis, and neurotoxicity,
we again administered CORT (20 mg/kg, s.c.) prior to MPTP,
METH, and TMT (Fig. 10). This anti-inflammatory treatment
shown to suppress neuroinflammation in these neurotoxicity
models (Fig. 9), failed to affect the activation of STAT3, induction
of GFAP, or loss of TH in the MPTP and METH models of
striatal neurotoxicity in the mouse, and also failed to suppress the
activation of STAT3 and induction of GFAP in the TMT model
of hippocampal neurotoxicity in the rat (Fig. 10). Together with
the data in Fig. 9, these findings indicate that damage caused by
diverse neurotoxicants induces neuroinflammation but that such
neuroinflammation is not necessarily responsible for the damage-
associated activation of STAT3, astrogliosis or neurotoxicity. The
data obtained for MPTP and METH are consistent with our data
showing suppression of neuroinflammation by minocycline, a non-
traditional immunosuppressant [42], in the MPTP and METH
models without affecting neurotoxicity [27].
Pro-inflammatory treatment with LPS results in enhanced
expression of proinflammatory ligands, and a CORT-
suppressible activation of STAT3, but not GFAP up
regulation
Taken together, the previous data indicate that damage due to
exposure to diverse neurotoxicants initiates neuroinflammation
but the observed neuroinflammatory responses were not linked to
activation of STAT3 and associated astrogliosis. Given these
observations, it seemed possible that activation of STAT3 also
could be dissociated from damage and astrogliosis, despite the fact
that multiple neurotoxicity models result in STAT3 activation
temporally linked to induction of GFAP. To examine this
possibility, we employed an acute exposure to the known
inflammogen, LPS, to induce neuroinflammation (Fig. 11). Our
prior experience suggested that acute administration of LPS did
not cause neurotoxicity or astrogliosis in any brain region (data not
shown). Acute LPS (2 mg/kg, i.p.), as expected, resulted in
enhanced expression of the proinflammatory cytokines/chemo-
kines, Tnf-a, Osm, Ccl2 and Lif (Fig. 11); data are shown for
mouse striatum, but similar results were observed for other brain
areas (data not shown). LPS also activated STAT3 over a 12-hr
post exposure period. The activation of STAT3 by LPS, unlike the
activation associated with multiple models of neurotoxicity, was
suppressible by acute pretreatment with CORT. The neuroin-
flammation and activation of STAT3 resulting from acute
Figure 11. LPS enhances expression of proinflammatory ligands, CORT-suppressible activation of STAT3, but not expression of
GFAP. Mice were administered LPS (2 mg/kg, s.c.), CORT (20 mg/kg) or CORT (20 mg/kg) 30 minutes prior to LPS (2 mg/kg). Mice were killed at the
post-dosing times indicated or at 6 hours post dosing for the LPS and CORT/LPS groups analyzed for pSTAT3tyr 705. Mice were killed by focused
microwave irradiation to preserve steady-state phosphorylation of pSTAT3tyr 705 and striatal phosphorylation was analyzed by quantification of scans
of pSTAT3tyr705 immunoblots. Separate groups of mice were used to prepare total striatal RNA from one side of the brain for qRT-PCR analysis of Tnf-
a, Osm, Ccl2 or Lif and to prepare total striatal protein homogenates from the other side of the brain for ELISA of GFAP. All data points represent mean
6 SEM, N=5. * denotes statistical significance of at least p,0.05 for the LPS alone and CORT/LPS groups compared to saline and# denotes statistical
significance of at least p,0.05 for CORT- pretreated LPS group compared to LPS only exposed group. Statistical significance was measured by one or
two-way ANOVA. Where significant differences were found, Fisher’s LSD Method of post hoc analysis was performed. See Methods for other details
on dosing regimens.
doi:10.1371/journal.pone.0102003.g011
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administration of LPS did not affect the expression of GFAP in
any brain region over a 72-hour time period (striatal data shown).
It was possible that the dosage and route of administration of LPS
we used were not sufficient to affect GFAP, as has been previously
reported [5]. Therefore, we administered LPS at 1–5 mg/kg, i.p.
and assayed GFAP levels in multiple brain regions at 24 hours
post exposure (Fig. 12). GFAP was not affected at any dose in any
region examined (Fig. 12). Together, these data serve to indicate
that ‘‘acute phase’’ neuroinflammation caused by LPS can activate
STAT3 without resulting in the classic feature associated with
astrogliosis (increased GFAP), findings consistent with gene
expression events shown for LPS, in vitro, without accompanying
increases in GFAP [43]. Thus, the STAT3 pathway appears to
serve as a dual ‘‘switch’’ for mediating acute neuroinflammatory
responses separate from its role in mediating damage-induced
astrogliosis.
Discussion
We demonstrate that the STAT3 pathway in astrocytes is
activated in diverse models of neurotoxicity-initiated astrogliosis,
regardless of the underlying mechanism of damage or the regional,
cellular or subcellular targets affected by each neurotoxicant.
Activation of STAT3 (phosphorylation at Tyr705) ensues rapidly
after the onset of neurotoxicity and prior to the induction of
GFAP, a STAT3 regulatory target [44,45]. Activation of STAT3
and subsequent induction of GFAP results from damage to
neuronal targets, not effects on astrocytes themselves, as protecting
neuronal targets from neurotoxicity also protects against activation
of STAT3 and enhanced expression of GFAP. Consistent with
these observations, STAT3 activation is restricted to the targeted
brain region, associated with translocation to the nucleus of
astrocytes after MPTP [12], METH and KA and its deletion in a
conditional knock-out abolishes the expression of GFAP in the
MPTP neurotoxicity model. Thus, based on our data obtained
with the multiple neurotoxicants examined to date, pSTAT3tyr705
appears to be a key signaling event underlying astrogliosis resulting
from divergent types of neurotoxicity affecting different CNS
targets. The ‘‘acute phase’’ response [46] exemplified by systemic
exposure to endotoxin (LPS) [47] also results in neuroinflamma-
tion and activation of the STAT3 pathway [48] but, in our hands,
without the up regulation of GFAP, a hallmark of reactive
astrogliosis, findings suggestive of a dissociation of the early
neuroinflammatory/microglial response to systemic infection from
the astroglial reaction linked to underlying neural damage. These
findings are summarized in Figure 13. In aggregate, our findings
not only support a general role of pSTAT3tyr705 in astrogliosis
signal transduction, but also suggest that pSTAT3tyr705 serves as
an early and broadly applicable biomarker of neurotoxicity.
Activation of STAT3 in response to systemic inflammation may
subserve a different role distinct from astroglial activation in
response to neural damage.
Relationship among enhanced expression of
proinflammatory mediators, activation of STAT3 and
astrogliosis
Our prior data with the MPTP neurotoxicity model was
suggestive of a role of proinflammatory cytokines/chemokines as
upstream effectors in the astrocytic JAK2/STAT3 cascade [12].
STAT3 is a major signaling component in inflammatory responses
[16,21,49–51] and proinflammatory cytokines that signal through
gp130 cause its dimerization and activation of JAK2, which in
turn phosphorylates Y705 on STAT3, triggering its translocation
to the nucleus [52,53]. Consequently, in the present study with
multiple neurotoxicants, as well as with the prior one limited to
MPTP, we examined the expression of gp130 ligands known to
activate the STAT3 pathway. In agreement with others [54], we
indeed found large-fold increases in the gp130 ligands, Osm and
Lif, across all of the diverse neurotoxic exposures with expression
time courses preceding those of pSTAT3tyr705 and of GFAP,
observations suggestive of upstream effector roles for these ligands
in the activation of the STAT3 signaling pathway and astrogliosis.
Large increases also were seen in Tnf-a and Ccl2 across the
various neurotoxicity models and these proinflammatory media-
tors could influence STAT3 signaling through various cross-talk
pathways (e.g., [13,55]). Our findings indicate that STAT3 is a
participant in neurotoxicity-induced astrogliosis because protect-
ing against neurotoxicity in multiple models blocks or greatly
Figure 12. Pro-inflammatory treatment with peripherally
injected LPS does not result in increased levels of GFAP at
24 h. Mice were administered LPS (1–5 mg/kg, i.p.) and killed at
24 hours post dosing. Total brain region homogenates were assayed for
GFAP by ELISA. All data points represent mean 6 SEM, N=5. Statistical
significance was measured by one-way ANOVA. See methods for dosing
regimen.
doi:10.1371/journal.pone.0102003.g012
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attenuates activation of STAT3 in addition to the induction of
GFAP. Moreover, eliminating STAT3 in a conditional knockout
nearly abolishes neurotoxicity-related expression of GFAP. Roles
for gp130 ligands in the induction of astrogliosis are less clear.
The data for all the neurotoxic insults we employed show a
consistent up regulation of Tnf-a, Osm, Ccl2 and Lif with a
temporal profile that precedes activation of STAT3 and an
enhanced expression of GFAP, findings consistent with microglial
activation in response to neurotoxicity [56]. While these effects
Figure 13. Different neurotoxic insults damage neurons in different brain areas, leading to astrocyte and microglia activation.
Activation of STAT3 (pTYR 705) represents a signaling event common to neurotoxic insults and neuroinflammation. Neurotoxicity-related damage
results in astrogliosis dependent on activation of STAT3 but does not require upstream signaling from proinflammatory cytokines and chemokines.
Suppression of this neuroinflammatory response to neurotoxicity does not affect expression of GFAP or pSTAT3. LPS causes brain-wide
neuroinflammation (represented by flames) characterized by activation of microglia and elaboration of proinflammatory cytokines/chemokines but
not neurodegeneration. Neuroinflammation-related activation of microglia due to LPS does not lead to astrogliosis but also is associated with
activation of STAT3 suppressible by glucocorticoids. Neuroinflammation likely activates a separate STAT3 pathway, perhaps in microglia.
Identification of upstream effectors in these STAT3 pathways will aid in defining and manipulating signal transduction events that likely play roles in
repair and neuroimmune responses.
doi:10.1371/journal.pone.0102003.g013
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clearly are related to neurotoxicity because they are blocked or
attenuated by neuroprotectants, our data do not define the source
of their expression or demonstrate their role in STAT3 signaling,
beyond a correlative time course. To address the potential linkage
between cytokine/chemokine expression and astrogliosis we
suppressed the proinflammatory responses resulting from MPTP
and METH neurotoxicity by pretreating with the tetracycline-like
anti-inflammatory compound, minocycline [27]. While minocy-
cline was effective in down-regulating the expression of all
cytokines/chemokines examined [27], it did not affect MPTP-
or METH-induced damage to dopaminergic nerve terminals, nor
did it alter astrogliosis as assessed by quantification of GFAP.
These data were suggestive of a dissociation of damage-related
microglial activation responses from subsequent influences on
neurotoxicity or the induction of astrogliosis. The data obtained in
the present study support this line of reasoning because
suppression of the expression of Tnf-a, Osm, Ccl2, and Lif by
acute pretreatment with the classic glucocorticoid anti-inflamma-
tory hormone, CORT, did not affect activation of STAT3, or
induction of GFAP in MPTP, METH and TMT models of
neurotoxicity. Suppressing neuroinflammation with CORT also
failed to suppress neurotoxicity due to MPTP and METH,
observations consistent with our prior finding with minocycline in
these models [27]. These data show that, at least for the case of
relatively selective neurotoxicity, damage results in neuroinflam-
mation but this constellation of proinflammatory responses does
not lead to activation of the STAT3 pathway or the induction of
astrogliosis, nor does neuroinflammation contribute to neurotox-
icity. These findings imply that neurodegeneration-induced
microglial activation can occur independently of astroglial
activation and that neurodegeneration causes neuroinflammation
but neuroinflammation does not necessarily contribute to
neurodegeneration. Indeed, this view is consistent with a role of
acute neuroinflammation in the initiation of regenerative respons-
es to neural injury [57,58].
Relationship among neuroinflammatory responses to
LPS, activation of STAT3 and astrogliosis
Systemic LPS results in an acute phase response that includes
activation of CNS microglia [59] and the brain-wide elaboration
of proinflammatory cytokines and chemokines (e.g., [60]).
Activation of STAT3 in the CNS also has been reported after
systemic administration of LPS [48,61,62]. Because the relation-
ship among neuroinflammation, STAT3 activation and astro-
gliosis, in the absence of CNS damage remains unclear, we
examined whether LPS-induced neuroinflammation would acti-
vate STAT3 and result in up regulation of GFAP as a marker of
astrogliosis. Large-fold increases in expression of the four
proinflammatory mediators affected by our panel of neurotox-
icants also were seen after LPS, but an activation of STAT3
followed without an induction in GFAP. Moreover, unlike the
activation of STAT3 and induction of GFAP seen after neurotoxic
exposures, suppression of pSTAT3 levels could be achieved with
anti-inflammatory pretreatment with CORT. While evidence has
been presented suggesting that LPS can over longer times cause
neural damage [5,63–66] and accompanying astrogliosis [67–69],
our findings here and previously [70], are consistent with an acute
and subacute elaboration of cytokines and chemokines as a
component of an innate immune response in brain [47,71]. These
neuroinflammatory effects of LPS may reflect a direct action on
astrocytes without up regulation of GFAP [43] over acute and
subacute times of 2 to 72 hours, or alternatively may reflect an
effect on STAT3 in microglia (Fig. 13). Microglial activation
responses, e.g. those mediating sickness behavior [22] represent
neuroimmune signaling that occur in the absence of brain damage
[59] and would not, therefore, be expected to be accompanied by
astrogliosis. Subsequent changes in GFAP at more chronic times
after LPS may reflect indirect reactive responses of astrocytes to
long term effects of LPS on other cells, including potential
neurodegenerative effects.
In aggregate, our data for neurotoxic exposures add to the
mounting evidence from other injury models showing that STAT3
signaling plays a dominant role in reactive gliosis [12,72–74].
While brain damage also initiates neuroinflammation, as noted
above, this latter response does not initiate astrogliosis. Neverthe-
less, CORT suppressible neuroinflammation in the absence of
damage may activate STAT3, perhaps in other cell types besides
astrocytes (e.g., microglia), a possibility that could be addressed in
future studies using the astrocyte specific STAT3-CKO mice
treated with LPS. We can conclude at this juncture that when
STAT3 activation is observed in the CNS, it may subserve
different roles depending on whether underlying neural damage is
involved as opposed to neuroinflammation alone.
Astrocyte heterogeneity now is becoming recognized at both the
molecular and cellular levels [75]. This heterogeneity also
encompasses astrocytic responses to injury across a variety of
damage models [8] Following traumatic injury, for example,
astrogliosis phenotypes differ with respect to the distance from the
site of injury and with respect to an involvement of a proliferative
response associated with astrocytic scarring [15]. These observa-
tions likely reflect a gradient of diffusible signals from blood
emanating from sites of BBB disruption [15,76]. STAT3 signaling
in astrocytes appears to be an obligatory component underlying all
these various reactive astrocytic responses to traumatic brain
injury. The neurotoxic insults employed in the present study differ
substantially from traumatic brain damage in that BBB is
preserved, a proliferative response is not observed even with
substantial neuronal damage (e.g. TMT, [77]) and the reactive
response is short-lived and resets to pre-exposure levels. Despite
these differences compared to traumatic injury, STAT3 activation
remains a common feature, findings suggestive of common
signaling modules. The glucocorticoid suppressible STAT3
pathway associated with neuroinflammation appears to represent
an alternate STAT3 pathway from the one involved in injury
(traumatic, neurotoxic, or disease). Clearly, an increased under-
standing of the diverse signaling molecules responsible for STAT3
activation in the CNS will be required to selectively affect its role
in astrogliosis and neuroinflammation.
Acknowledgments
We appreciate the excellent technical assistance provided by Brenda K.
Billig and Christopher M. Felton and gratefully acknowledge the useful
discussions with Dr. Krishnan Sriram.
Author Contributions
Conceived and designed the experiments: JPO DBM MVS KAK.
Performed the experiments: KAK RLV JPO. Analyzed the data: KAK
JPO DBM. Contributed reagents/materials/analysis tools: KAK RLV
MVS JPO. Contributed to the writing of the manuscript: KAK JPO DBM
MVS.
STAT3 Regulates Astrogliosis Induced by Neurotoxicity
PLOS ONE | www.plosone.org 15 July 2014 | Volume 9 | Issue 7 | e102003
References
1. Norton WT, Aquino DA, Hozumi I, Chiu FC, Brosnan CF (1992) Quantitative
aspects of reactive gliosis: a review. Neurochem Res 17:877–885.
2. O’Callaghan JP (1993) Quantitative features of reactive gliosis following
toxicant-induced damage of the CNS. Ann N Y Acad Sci 679:195–210.
3. Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-
thirty-one years (1969-2000). Neurochem Res 25:1439–1451.
4. Norenberg MD, Rao KV, Jayakumar AR (2005) Mechanisms of ammonia-
induced astrocyte swelling. Metab Brain Dis 20:303–318.
5. Zamanian JL, Xu L, Foo LC, Nouri N, Zhou L, et al. (2012) Genomic analysis
of reactive astrogliosis. J Neurosci 32:6391–6410.
6. Eng LF (1985) Glial fibrillary acidic protein (GFAP): the major protein of glial
intermediate filaments in the differentiated astrocytes. J Neuroimmunol 8(4-
6):203–14.
7. Penky M, Wilhelmsson U, Penka M (2014) The dual role of astrocyte activation
and reactive gliosis. Neuroscience Letters 565:30–38.
8. Sofroniew MV (2009) Molecular dissection of reactive astrogliosis and glial scar
formation. Trends Neurosci 32:638–647.
9. Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. Acta
Neuropathol 119:7–35.
10. Sosunov AA, Wu X, Tsankova NM, Guilfoyle E, McKhann GM 2nd, et al.
(2014) Phenotypic heterogeneity and plasticity of isocortical and hippocampal
astrocytes in the human brain. J Neurosci 34(6):2285–2298.
11. O’Callaghan JP, Sriram K (2005) Glial fibrillary acidic protein and related glial
proteins as biomarkers of neurotoxicity. Expert Opin Drug Saf 4:433–442.
12. Sriram K, Benkovic SA, Hebert MA, Miller DB, O’Callaghan JP (2004)
Induction of gp130-related cytokines and activation of JAK2/STAT3 pathway
in astrocytes precedes up-regulation of glial fibrillary acidic protein in the 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of neurodegeneration: key
signaling pathway for astrogliosis in vivo? J Biol Chem 279:19936–19947.
13. Chen E, Xu D, Lan X, Jia B, Sun L, et al. (2013) A Novel Role of the STAT3
Pathway in Brain Inflammation-induced Human Neural Progenitor Cell
Differentiation. Curr Mol Med 13:1474–84.
14. O’Callaghan JP, Sriram K, Miller DB (2008) Defining ‘‘neuroinflammation’’.
Ann N Y Acad Sci 1139:318–330.
15. Wanner IB, Anderson MA, Song B, Levine J, Fernandez A, et al. (2013) Glial
Scar Borders Are Formed by Newly Proliferated, Elongated Astrocytes That
Interact to Corral Inflammatory and Fibrotic Cells via STAT3-Dependent
Mechanisms after Spinal Cord Injury. J Neurosci 33:12870–12886.
16. Oliva AA, Kang Y, Sanchez-Molano J, Furones C, Atkins CM (2012) STAT3
signaling after traumatic brain injury. J Neurochem 120:710–720.
17. Herrmann JE, Imura T, Song B, Qi J, Ao Y, et al. (2008) STAT3 is a critical
regulator of astrogliosis and scar formation after spinal cord injury. J Neurosci
28:7231–7243.
18. Okada S, Nakamura M, Katoh H, Miyao T, Shimazaki T, et al. (2006)
Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes
after spinal cord injury. Nat Med 12(7):829–834.
19. Dinapoli VA, Benkovic SA, Li X, Kelly KA, Miller DB, et al. (2010) Age
exaggerates proinflammatory cytokine signaling and truncates signal transducers
and activators of transcription 3 signaling following ischemic stroke in the rat.
Neuroscience 170:633–644.
20. Deng H, Han HS, Cheng D, Sun GH, Yenari MA (2003) Mild hypothermia
inhibits inflammation after experimental stroke and brain inflammation. Stroke
34:2495–2501.
21. Bauer S, Kerr BJ, Patterson PH (2007) The neuropoietic cytokine family in
development, plasticity, disease and injury. Nat Rev Neurosci 8:221–232.
22. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From
inflammation to sickness and depression: when the immune system subjugates
the brain. Nat Rev Neurosci 9:46–56.
23. O’Callaghan JP, Miller DB (2010) Spinal glia and chronic pain. Metabolism
59:S21–6.
24. O’Callaghan JP (1991) Quantification of glial fibrillary acidic protein:
comparison of slot-immunobinding assays with a novel sandwich ELISA.
Neurotoxicol Teratol 13:275–281.
25. O’Callaghan JP (2002) Measurement of glial fibrillary acidic protein. Curr
Protoc Toxicol Chapter 12:Unit12.
26. O’Callaghan JP, Miller DB, Reinhard JF, Jr. (1990) Characterization of the
origins of astrocyte response to injury using the dopaminergic neurotoxicant, 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res 521:73–80.
27. Sriram K, Miller DB, O’Callaghan JP (2006) Minocycline attenuates microglial
activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor
necrosis factor-alpha. J Neurochem 96:706–718.
28. Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, et al. (1998) Stat3
activation is responsible for IL-6-dependent T cell proliferation through
preventing apoptosis: generation and characterization of T cell-specific Stat3-
deficient mice. J Immunol 161:4652–4660.
29. O’Callaghan JP, Miller DB (1994) Neurotoxicity profiles of substituted
amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741–751.
30. O’Callaghan JP, Jensen KF, Miller DB (1995) Quantitative aspects of drug and
toxicant-induced astrogliosis. Neurochem Int 26:115.
31. O’Callaghan JP, Sriram K (2004) Focused microwave irradiation of the brain
preserves in vivo protein phosphorylation: comparison with other methods of
sacrifice and analysis of multiple phosphoproteins. J Neurosci Methods 135:159–
168.
32. Scharf MT, Mackiewicz M, Naidoo N, O’Callaghan JP, Pack AI (2008) AMP-
activated protein kinase phosphorylation in brain is dependent on method of
killing and tissue preparation. J Neurochem 105:833–841.
33. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, et al. (1985)
Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85.
34. Cromey DW (2007) Avoiding twisted pixels: ethical guidelines for the
appropriate use of manipulation of scientific digital images. Sci Eng Ethics
16:639–667.
35. Sedgewick J (2013) Image Integrity: Scientific Do’s and Don’ts. www.
imagingandanalysis.com/courses_image_integrity.
36. Miller DB, O’Callaghan JP (1994) Environment-, drug- and stress-induced
alterations in body temperature affect the neurotoxicity of substituted
amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:752–760.
37. Kelly KA, Miller DB, Bowyer JF, O’Callaghan JP (2012) Chronic exposure to
corticosterone enhances the neuroinflammatory and neurotoxic responses to
methamphetamine. J Neurochem 122:995–1009.
38. Benkovic SA, O’Callaghan JP, Miller DB (2004) Sensitive indicators of injury
reveal hippocampal damage in C57BL/6J mice treated with kainic acid in the
absence of tonic-clonic seizures. Brain Res. 1024(1–2):59–76.
39. Fuller TA, Olney JW (1981) Only certain anticonvulsants protect against kainate
neurotoxicity. Neurobehav Toxicol Teratol 3:355–361.
40. Murray PJ (2007) The JAK-STAT signaling pathway: Input and output
integration. J Immunol 178:2623–2629.
41. Nicolas CS, Amici M, Bortolotto ZA, Doherty A, Csaa Z, et al. (2013) The role
of JAK-STAT signaling in the CNS. JAK-STAT 2013; 2:e22925; http://dx.doi.
org/10.4161/jkst.22925.
42. Garrido-Mesa N, Zarzuelo A, Galvez J (2013) Minocycline: far beyond an
antibiotic. Br J Pharmacol 169(2):337–52.
43. Hamby ME, Coppola G, Ao Y, Geschwind DH, Khakh BS, et al. (2012)
Inflammatory mediators alter the astrocyte transcriptome and calcium signaling
elicited by multiple G-protein-coupled receptors. J Neurosci. 32: 14489–14510.
44. Zhong Z, Wen Z, Darnell JE, Jr. (1994) Stat3: a STAT family member activated
by tyrosine phosphorylation in response to epidermal growth factor and
interleukin-6. Science 264:95–98.
45. Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, et al. (2004) IL-6 plays an
obligatory role in late preconditioning via JAK-STAT signaling and upregula-
tion of iNOS and COX-2. Cardiovasc Res 64:61–71.
46. Bengmark S (2004) Acute and ‘‘chronic’’ phase reaction-a mother of disease.
Clin Nutr 23:1256–1266.
47. Dantzer R, Kelley KW (2007) Twenty years of research on cytokine-induced
sickness behavior. Brain Behav Immun 21:153–160.
48. Gautron L, Lafon P, Chaigniau M, Tramu G, Laye S (2002) Spatiotemporal
analysis of signal transducer and activator of transcription 3 activation in rat
brain astrocytes and pituitary following peripheral immune challenge.
Neuroscience 112:717–729.
49. Lebel E, Vallieres L, Rivest S (2000) Selective involvement of interleukin-6 in the
transcriptional activation of the suppressor of cytokine signaling-3 in the brain
during systemic immune challenges. Endocrinology 141:3749–3763.
50. Rivest S, Lacroix S, Vallieres L, Nadeau S, Zhang J, et al. (2000) How the blood
talks to the brain parenchyma and the paraventricular nucleus of the
hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc
Exp Biol Med 223:22–38.
51. Turner RC, Lucke-Wold B, Miller DB, O’Callaghan JP, Rosen CL, et al. (2012)
Neuropoietic cytokines and neural injury: alterations in JAK2/STAT3 signaling
associated with aging. In: Neurological Disorders: New Research ( Thomas CE,
Moore JR, eds), pp 27–48. Nova Science Publishers, Inc.
52. Darnell JE Jr (1997) STATs and gene regulation. Science 277:1630–1635.
53. Leonard WJ, O’Shea JJ (1998) Jaks and STATs: biological implications. Annu
Rev Immunol 16:293–322.
54. Thomas DM, Francescutti-Verbeem DM, Liu X, Kuhn DM (2004) Identifica-
tion of differentially regulated transcripts in mouse striatum following
methamphetamine treatment-an oligonucleotide microarray approach.
J Neurochem 88:380–393.
55. Miscia S, Marchisio M, Grilli A, Di Valerio V, Centurione L, et al. (2002)
Tumor necrosis factor alpha (TNF-alpha) activates Jak1/Stat3-Stat5B signaling
through TNFR-1 in human B cells. Cell Growth Differ 13(1):13–8.
56. Aguzzi A, Barres BA, Bennett ML (2013) Microglia: Scapegoat, Saboteur, or
Something Else? Science 339:156–161.
57. Kyritsis N, Kizil C, Zocher S, Kroehne V, Kaslin J, et al. (2012) Acute
inflammation initiates the regenerative response in the adult zebrafish brain.
Science 338:1353–1356.
58. Stella N (2012) Inflammation to Rebuild a Brain. Science 338:1303–1304.
59. Buttini M, Limonta S, Boddeke HWGM (1996) Peripheral administration of
lipopolysaccharide induces activation of microglial cells in rat brain. Neurochem
Int 29:25–35.
60. Datta SC, Opp MR (2008) Lipopolysaccharide-induced increases in cytokines in
discrete mouse brain regions are detectable using Luminex xMAP technology.
J Neurosci Methods 175:119–124.
STAT3 Regulates Astrogliosis Induced by Neurotoxicity
PLOS ONE | www.plosone.org 16 July 2014 | Volume 9 | Issue 7 | e102003
61. Meddahi A, Bree F, Papy-Garcia D, Gautron J, Barritault D, et al. (2002)
Pharmacological studies of RGTA(11), a heparan sulfate mimetic polymer,
efficient on muscle regeneration. J Biomed Mater Res 62:525–531.
62. Beurel E, Jope RS (2009) Lipopolysaccharide-induced interleukin-6 production
is controlled by glycogen synthase kinase-3 and STAT3 in the brain.
J Neuroinflammation 6:9.
63. Al-Amri JS, Hagras MM, Mohamed IM (2013) Effect of epigallocatechin-3-
gallate on inflammatory mediators release in LPS-induced Parkinson’s disease in
rats. Indian J Exp Biol 51:357–362.
64. Qin L, Wu X, Block ML, Liu Y, Breese GR, et al. (2007) Systemic LPS causes
chronic neuroinflammation and progressive neurodegeneration. Glia 55:453–
462.
65. Nguyen TA, Frank-Cannon T, Martinez TN, Ruhn KA, Marvin M, et al. (2013)
Analysis of inflammation-related nigral degeneration and locomotor function in
DJ-1(-/-) mice. J Neuroinflammation 10:50.
66. Qin L, Liu Y, Hong JS, Crews FT (2013) NADPH oxidase and aging drive
microglial activation, oxidative stress, and dopaminergic neurodegeneration
following systemic LPS administration. Glia 61:855–868.
67. Kaya M, Palanduz A, Kalayci R, Kemikler G, Simsek G, et al. (2004) Effects of
lipopolysaccharide on the radiation-induced changes in the blood-brain barrier
and the astrocytes. Brain Res 1019:105–112.
68. Semmler A, Okulla T, Sastre M, Dumitrescu-Ozimek L, Heneka MT (2005)
Systemic inflammation induces apoptosis with variable vulnerability of different
brain regions. J Chem Neuroanat 30:144–157.
69. Ifuku M, Katafuchi T, Mawatari S, Noda M, Miake K, et al. (2012) Anti-
inflammatory/anti-amyloidogenic effects of plasmalogens in lipopolysaccharide-
induced neuroinflammation in adult mice. J Neuroinflammation 9:197.
70. Little AR, Benkovic SA, Miller DB, O’Callaghan JP (2002) Chemically induced
neuronal damage and gliosis: enhanced expression of the proinflammatory
chemokine, monocyte chemoattractant protein (MCP)-1, without a correspond-
ing increase in proinflammatory cytokines(1). Neuroscience 115:307–320.
71. Dantzer R (2004) Cytokine-induced sickness behaviour: a neuroimmune
response to activation of innate immunity. Eur J Pharmacol 500:399–411.
72. Xia H, Wang Q, Liao Y, Xu X, Baxter SM, et al. (2002) Polymerization rate
and mechanism of ultrasonically initiated emulsion polymerization of n-butyl
acrylate. Ultrason Sonochem 9:151–158.
73. Choi JS, Kim SY, Cha JH, Choi YS, Sung KW, et al. (2003) Upregulation of
gp130 and STAT3 activation in the rat hippocampus following transient
forebrain ischemia. Glia 41:237–246.
74. Tsuda M, Kohro Y, Yano T, Tsujikawa T, Kitano J, et al. (2011) JAK-STAT3
pathway regulates spinal astrocyte proliferation and neuropathic pain mainte-
nance in rats. Brain 134:1127–1139.
75. Zhang Y, Barres BA (2010) Astrocyte heterogeneity: an underappreciated topic
in neurobiology. Curr Opin Neurobiol 20:588–594.
76. Shigetomi E, Bushong EA, Haustein MD, Tong X, Jackson-Weaver O, et al.
(2013) Imaging calcium microdomains within entire astrocyte territories and
endfeet with GCaMPs expressed using adeno-associated viruses. J Gen Physiol
141:633–647.
77. Brock TO, O’Callaghan JP (1987) Quantitative changes in the synaptic vesicle
proteins synapsin I and p38 and the astrocyte-specific protein glial fibrillary
acidic protein are associated with chemical-induced injury to the rat central
nervous system. J Neurosci 7:931–942.
STAT3 Regulates Astrogliosis Induced by Neurotoxicity
PLOS ONE | www.plosone.org 17 July 2014 | Volume 9 | Issue 7 | e102003
